Stegh, AlexanderKim, HyunggeeBachoo, RobertForloney, KristinZhang, JeanSchulze, HaraldPark, KevinHannon, GregoryYuan, JunyingLouis, DavidDePinho, RonaldChin, Lynda2019-10-052007Stegh, A. H., H. Kim, R. M. Bachoo, K. L. Forloney, J. Zhang, H. Schulze, K. Park, et al. 2007. “Bcl2L12 Inhibits Post-Mitochondrial Apoptosis Signaling in Glioblastoma.” Genes & Development 21 (1): 98–111. https://doi.org/10.1101/gad.1480007.0890-93691549-5477http://nrs.harvard.edu/urn-3:HUL.InstRepos:41483449Glioblastoma ( GBM) is an astrocytic brain tumor characterized by an aggressive clinical course and intense resistance to all therapeutic modalities. Here, we report the identification and functional characterization of Bcl2L12 ( Bcl2-like-12) that is robustly expressed in nearly all human primary GBMs examined. Enforced Bcl2L12 expression confers marked apoptosis resistance in primary cortical astrocytes, and, conversely, its RNA interference ( RNAi)-mediated knockdown sensitizes human glioma cell lines toward apoptosis in vitro and impairs tumor growth with increased intratumoral apoptosis in vivo. Mechanistically, Bcl2L12 expression does not affect cytochrome c release or apoptosome-driven caspase-9 activation, but instead inhibits post-mitochondrial apoptosis signaling at the level of effector caspase activation. One of Bcl2L12's mechanisms of action stems from its ability to interact with and neutralize caspase-7. Notably, while enforced Bcl2L12 expression inhibits apoptosis, it also engenders a pronecrotic state, which mirrors the cellular phenotype elicited by genetic or pharmacologic inhibition of post-mitochondrial apoptosis molecules. Thus, Bcl2L12 contributes to the classical tumor biological features of GBM such as intense apoptosis resistance and florid necrosis, and may provide a target for enhanced therapeutic responsiveness of this lethal cancer.en-USJournal Article2019-10-0510.1101/gad.1480007